Page last updated: 2024-11-09

mitobronitol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mitobronitol: Brominated analog of MANNITOL which is an antineoplastic agent appearing to act as an alkylating agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID656655
CHEMBL ID447629
CHEBI ID34853
SCHEMBL ID8500
MeSH IDM0013936

Synonyms (65)

Synonym
smr000058654
1,6-dibromo-1,6-dideoxy-d-mannitol
MLS000028841
mitobronitol
myebrol
nci-c04762
dibromannitol
1,6-dibromomannitol
mielobromol
myelobromol
dibromannit
nsc-94100
r 54
1,6-dibromo-d-mannitol
dibromomannitol
brn 1721919
(2s,3s,4s,5s)-1,6-dibromohexane-2,3,4,5-tetrol
1,6-dibromo-1,6-dideoxymannitol
mannitol, 1,6-dibromo-1,6-dideoxy-, d-
ccris 2750
ai3-52331
mitobronitol [inn:ban:dcf:jan]
d-mannitol, 1,6-dibromo-1,6-dideoxy-
1,6-dibrom-1,6-didesoxy-d-mannit [german]
1,6-dideoxy-1,6-dibromo-d-mannitol
1,6-dibromo-1,6-d-didesoxymannitol
einecs 207-676-8
1,6-dideoy-1,6-dibromo-d-mannitol
mitobronitolum [inn-latin]
MLS001074881
NCGC00091099-02 ,
mitobronitol (jan/inn)
D02020
chebi:34853 ,
CHEMBL447629
NCGC00091099-03
ST075185 ,
(2s,3s,4s,5s)-1,6-dibromohexane-2,3,4,5-tetraol
tox21_201164
NCGC00258716-01
cas-488-41-5
dtxsid7022918 ,
dtxcid502918
tox21_111079
HMS2231P10
3-01-00-02373 (beilstein handbook reference)
mitobronitolum
5up30yed7n ,
1,6-dibrom-1,6-didesoxy-d-mannit
unii-5up30yed7n
mitobronitol [mi]
mitobronitol [mart.]
mitobronitol [who-dd]
mitobronitol [jan]
mitobronitol [inn]
SCHEMBL8500
AKOS024284362
SR-01000763290-2
sr-01000763290
DB13543
bis(p-chlorophenyl) methane
16dibromo16dideoxydmannitol
CS-0007507
HY-13641
F76873

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The mannitol derivatives were selectively myelosuppressive, being twice as toxic towards granulocytes as towards lymphocytes."( Toxicity, antitumour and haematological effects of 1,2-anhydro-6-bromogalactitol and d-mannitol: a comparison with the related dibromo- and dianhydro-derivatives.
Hegedüs, L; Horváth, IP; Jarman, M; Somfai-Relle, S, 1982
)
0.26

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
alcoholA compound in which a hydroxy group, -OH, is attached to a saturated carbon atom.
organobromine compoundA compound containing at least one carbon-bromine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
TDP1 proteinHomo sapiens (human)Potency14.96920.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency33.49150.000221.22318,912.5098AID743040
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency31.62280.707912.194339.8107AID720542
thyroid stimulating hormone receptorHomo sapiens (human)Potency27.25050.001628.015177.1139AID1259385
gemininHomo sapiens (human)Potency13.33590.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.51030.005612.367736.1254AID624032
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency17.78280.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID384212Mutagenic activity in Salmonella Typhimurium TA100 assessed as logarithm of his+ revertant number increasing activity by amens test2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity.
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199039 (60.94)18.7374
1990's9 (14.06)18.2507
2000's8 (12.50)29.6817
2010's6 (9.38)24.3611
2020's2 (3.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.24 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (7.69%)5.53%
Reviews9 (13.85%)6.00%
Case Studies9 (13.85%)4.05%
Observational0 (0.00%)0.25%
Other42 (64.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]